Benchmark upgraded Nephros to Speculative Buy from Hold with a $5 price target after the company reported “solid” results for Q4 and 2023 as a whole. The firm, which forecasts that Nephros will post revenues of $17.1M, up 20% year-over-year in FY24, sees a “positive outlook and quarterly comparisons going forward.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NEPH: